Trials / Not Yet Recruiting
Not Yet RecruitingNCT07358377
To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor
An Open-Label, Multi-Center Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant or Letrozole in Patients With Solid Tumor
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Atridia Pty Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-6209 Capsules and fulvestrant injection | HRS-6209, 100mg BID for 4 weeks, and single dose of fulvestrant injection |
Timeline
- Start date
- 2026-03-15
- Primary completion
- 2027-04-10
- Completion
- 2027-11-10
- First posted
- 2026-01-22
- Last updated
- 2026-01-22
Source: ClinicalTrials.gov record NCT07358377. Inclusion in this directory is not an endorsement.